Our Labs

Gustafson Lab

Led by Dr. Heather Gustafson, EDIT Labs develops novel technology platforms that target and alter macrophage phenotypes.

Kalia Lab

The Kalia Lab is enabling progress toward immunotherapies that can be applied to any type of cancer.

Lawlor Lab

The Lawlor Lab research focuses on Ewing sarcoma, an aggressive bone and soft tissue tumor for which new cures are needed.

Myron Evans II Lab

The Myron Evans II Lab is working to better understand why children get brain tumors and which mutations drive those tumors. This research includes studying how the brain normally develops in mammals, and how that process goes wrong and causes brain tumors. The lab is also working to identify new targets that could lead to potential clinical trials for children. Our ultimate goal is to make discoveries that inform a new wave of brain tumor treatments that are more targeted than today’s therapies, with fewer side effects.

Oda Lab

We develop engineering strategies that enable T cells to overcome obstacles in the tumor microenvironment and mount a more powerful, durable and sustained attack on cancer cells.

Orentas Lab

The Orentas Lab investigates how the immune system and CAR T-cell immunotherapies can be leveraged to fight childhood childhood cancers like rhabdomyosarcoma, osteosarcoma, Ewing’s sarcoma and neuroblastoma.

Pattwell Lab

The Pattwell Lab studies the genes and processes involved in normal neurodevelopment and how they are hijacked in the context of cancer. Better understanding of normal developmental processes can help scientists pinpoint exactly when and where certain processes go wrong in tumors. This can inform therapies that target those processes —with the ultimate goal of creating more targeted cancer treatments with fewer side effects.

Sarkar Lab

The Sarkar Lab is finding ways to help the immune system remember cancer and attack it if it relapses – whether that’s months or decades after a child goes into remission.

Vitanza Lab

The Vitanza lab searches for new treatments that are both safe and curative for aggressive pediatric brain and spinal cord tumors, such as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma H3 K27M-mutant (DMG), and atypical teratoid rhabdoid tumor (ATRT).